SARS-CoV-2尖端蛋白导致突触功能障碍和p-tau和α-synuclein聚合导致认知障碍:甲胺的保护作用
Hye-Kyung Lee1, Ji Young Choi1, Jung Hyun Park1
1Division of Brain Diseases Research, Department of Chronic Disease Convergence Research, Korea National Institute of Health, Cheongju-si, Republic of Korea.
PloS one
|November 7, 2025
概括
SARS-CoV-2 S1 蛋白质通过破坏突触功能和促进神经退行导致认知障碍. 甲胺可能提供一种治疗策略,以缓解长期的COVID-19认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 后COVID-19认知功能障碍是一个持续的挑战.
- 目前正在调查SARS-CoV-2尖端蛋白在长期神经效应中的作用.
- 将SARS-CoV-2感染与认知障碍联系在一起的机制需要阐明.
研究的目的:
- 研究SARS-CoV-2 S1蛋白如何诱导认知障碍.
- 探索甲胺对S1诱导的认知缺陷的治疗潜力.
- 确定涉及S1介导神经毒性的分子途径.
主要方法:
- 在小鼠模型中注射SARS-CoV-2 S1蛋白.
- 对海马组织的转录基因分析.
- 评估HIF-1α信号传递,突触基因表达,神经元损失和蛋白质聚合.
- 评估甲福明在减轻S1效应方面的疗效.
主要成果:
- S1蛋白迅速进入海马,导致认知障碍在6周内.
- S1改变了突触和缺氧反应性基因表达,稳定了HIF-1α.
- 击败HIF-1α恢复了突触基因表达.
- S1诱导的神经元损失,酸化的,和α-synuclein聚合.
- 甲胺治疗挽救了突触基因表达和减少了蛋白质聚合.
结论:
- SARS-CoV-2 S1 蛋白质破坏海马突触平衡,并促进神经退行.
- 在S1诱导的突触功能障碍中,HIF-1α信号传递起着至关重要的作用.
- 甲胺显示出作为治疗剂的潜力,可以缓解COVID-19的长期认知后果.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Long-term Depression
3.1K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
802
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
802


